白细胞介素-2受体拮抗剂用于儿童肝移植受者的系统评价和对照研究的荟萃分析
Interleukin-2 receptor antagonists for pediatric liver transplant recipients: A systematic review and meta-analysis of controlled studies
摘要:
白细胞介素-2受体拮抗剂(IL-2 RA)常用作肝移植受者的诱导治疗,以降低急性排斥反应的风险,同时减少伴随的免疫抑制。然而,与使用IL-2 RA的确切关联尚不确定。我们对相关研究进行了系统的文献检索。随机效应模型用于评估急性排斥反应、激素抵抗性排斥反应、移植物丢失、患者死亡和药物不良反应的发生率,有或无IL-2 RA。6项研究(2项随机和4项非随机)符合入选标准。6个月或更晚的急性排斥反应显著有利于使用IL-2 RA(相对风险(RR)0.38; 95%置信区间(CI)0.22-0.66,p = 0.0005)。尽管没有统计学显著性,但IL-2 RA显示类固醇耐药排斥反应的风险显著降低(RR 0.32; CI 0.19-1.03,p = 0.0594)。通过使用IL-2 RA,移植物丢失和患者死亡显示出减少的趋势。使用IL-2 RA是安全的,并且与移植后急性排斥反应的发生率统计学显著降低以及类固醇耐受性排斥反应、移植物丢失和患者死亡的显著减少相关。
英文摘要:
Interleukin-2 receptor antagonists (IL-2RA) are frequently used as induction therapy in liver transplant recipients to decrease the risk of acute rejection while allowing the reduction of concomitant immunosuppression. The exact association with the use of IL-2RA however is uncertain. We performed a systematic literature search for relevant studies. Random effects models were used to assess the incidence of acute rejection, steroid-resistant rejection, graft loss, patient death, and adverse drug reaction, with or without IL-2RA. Six studies (2 randomized and 4 nonrandomized) met the elegibility criteria. Acute rejection at 6 months or later favored the use of IL-2RA significantly (relative risk (RR) 0.38; 95% confidence interval (CI) 0.22-0.66, p = 0.0005). Although not statistically significant, IL-2RA showed a substantial reduction of the risk of steroid-resistant rejection (RR 0.32; CI 0.19-1.03, p = 0.0594). Graft loss and patient death showed a reductive tendency through the use of IL-2RA. The use of IL-2RA is safe and is associated with a statistically significantly lower incidence of acute rejection after transplantation and substantial reduction of steroid-resistant rejection, graft loss and patient death.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。